Background: Spinocerebellar Ataxia type 3 (SCA3, also known as Machado-Joseph disease) 28 is a neurodegenerative disorder caused by a CAG repeat expansion encoding an abnormally 29 long polyglutamine (polyQ) tract in the disease protein, ataxin-3 (ATXN3). No preventive 30
4
Here, we carried out an unbiased druggable genome siRNA screen in a cell-based assay to 77 identify genes and pathways that modulate levels of expanded-polyQ ATXN3. Downstream 78 validation of identified genes was then performed in Drosophila models of SCA3 and neuronal 79 progenitor cells (NPCs) derived from human embryonic stem cells (hESCs) harboring an 80 expanded CAG repeat in ATXN3. We identified novel genes that regulate ATXN3 levels in 81 mammalian cells and modulate mutant ATXN3-mediated toxicity in Drosophila, suggesting new 82 therapeutic targets in SCA3 and perhaps similar disorders. 83 84
Materials and Methods 85 86
Druggable genome siRNA primary screen 87
High-throughput screens were carried out at the University of Michigan Center for Chemical 88 Genomics (CCG). We screened the druggable genome subset of the human siGENOME siRNA 89
SMARTpool library (Dharmacon) targeting 2742 genes. Each library stock plate comprising 280 90 siRNA SMART-pools targeting druggable genes and four internal library siRNA controls for 91 viability at 500 nM was screened in triplicate by reverse transfection of stably transfected 92 293/ATXN3Q81:FF-Luc (ATXN3-Luc) cells. Sample siRNAs were screened at a final 93 concentration of 50 nM and control siGENOME siRNAs and 94 SMARTpools for ATXN3 and BECLN1) at 20 nM. siRNAs (4 µL) were transferred from each 95 library stock plate (500 nM) and a control stock plate (200 nM) to three 384-well black tissue 96 culture-treated assay plates (Greiner-Bio CellStar) using Biomek FX (Beckman Coulter, 97 Fullerton, CA) ( Supplementary Figure 1) . Lipofectamine RNAiMAX transfection reagent (Thermo 98
Fisher Scientific) was diluted in OPTIMEM (Thermo Fisher Scientific) (0.1 µL of RNAiMax + 5.9 99 µL of OPTIMEM) and 6 µL of the mixture were added per well to the assay plates containing the 100 siRNAs using an automated dispenser (Multidrop Combi, Thermo Fisher) . Plates were briefly 101 Induction Medium (NIM)/ SMADi/ 10 µM Y-27632 and plated in one well of a 6-well plate coated 140 with poly-L-ornithine (PLO) and laminin (lam) and incubated at 37°C, 5% CO2. Daily full medium 141 changes were performed with NIM/ SMADi until Day 6, when cells (80-90% confluent) were 142 passaged into two 60 mm plates coated with PLO/lam (P1) using ACCUTASE and NIM/ SMADi/ 143 10 µM Y-27632. Medium was changed daily and cells were passaged as above at Day 10 (P2). 144
At Day 13 (P3), cells were passaged and plated in STEMdiff Neural Progenitor Medium (NPM) 145 and since then cells were expanded and maintained in NPM. Control and SCA3 NPCs (P4) 146
were evaluated for expression of NPC markers and cells of passage four or higher were frozen 147 in STEMdiff Neural Progenitor Freezing Medium in liquid nitrogen. Cells were thawed and re-148 expanded as needed for experiments. 149 150
Electroporation of SCA3 neuronal progenitor cells (NPCs) 151
Approximately 10 6 SCA3 NPCs (P8-P11) were electroporated with 1 µg of pCMV-152 SPORT6.FBXL3 (Dharmacon, MHS6278-202759846) For all stocks and for experimental procedures, adult males and virgin females were crossed, 202 raised and maintained at 25°C under diurnal conditions in standard cornmeal media. All 203 examined flies were heterozygous for driver and transgenes. Once offspring emerged from 204 pupal cases, they were aged under the same conditions described above for seven days, at 205 which time heads were dissected and imaged using an Olympus BX53 microscope equipped 206 with a DP72 digital camera for GFP fluorescence experiments, or whole flies were fixed and 207 processed for histological sections, described below. Fluorescence from each eye was 208 quantified using the publicly available ImageJ software. Average retinal fluorescence for each 209 treatment condition was calculated as previously described [23] [24] [25] [26] [27] . RNAi fly lines used for the 210 work described in this manuscript are listed in Supplementary Table 2 . The GMR-Gal4 driver 211 (#8605) and UAS-mCD8-GFP (#5137) were from the Bloomington Drosophila Stock center. The 212 UAS-ataxin-3Q77 line has been described before [13, 28] . For histological sections, adult fly 213 wings and proboscises were removed, and flies were fixed in 2% glutaraldehyde/ 2% 214 paraformaldehyde in Tris-buffered saline with 0.1% Triton X-100. The fixed flies were 215 dehydrated in a series of 30%, 50%, 75%, and 100% ethanol, and 100% propylene oxide. 216
Dehydrated specimens were embedded in Poly/Bed812 (Polysciences) and fly heads were 217 sectioned at 5 µm. Sectioned heads were stained with toluidine blue. 218 219
Bioinformatic analysis 220
Gene lists were analyzed for biological functions and network analysis was performed with the 221 Ingenuity Pathway Analysis software (Qiagen) using the whole-human genome as the reference 222 gene set and known direct and indirect gene relationships. To identify genes that regulate levels of pathogenic ATXN3 in mammalian cells, we used our 232 previously developed ATXN3-Luc cellular assay ( Figure 1A,B) [13] to screen the druggable 233 genome subset of the human siGENOME siRNA library (Dharmacon). This library comprises 234
SMARTpools of four individual siRNAs targeting 2742 genes that are considered potential 235 therapeutic targets, including G-protein coupled receptors (GPCRs), ion channels, protein 236 kinases, proteases, phosphatases and ubiquitin conjugation enzymes 237 (https://dharmacon.horizondiscovery.com/rnai/). The ATXN3-Luc assay measures 238 chemiluminescence in HEK293 cells stably overexpressing FLAG-tagged human ATXN3 239
harboring an expanded polyQ repeat in the disease range (Q81) fused to firefly Luciferase, 240 under the control of a CMV promoter ( Figure 1A ,B) [13] . We reasoned that by screening for 241 steady state levels of the ATXN3/Luciferase fusion protein (reported as chemiluminescence), 242 and because its expression is driven by the CMV promoter, we would identify genes that 243 regulate ATXN3 abundance at post-transcriptional steps (e.g. mRNA stability/degradation, and 244 protein translation, folding and turnover). To circumvent false-positive siRNAs that interfere with 245 CMV promoter activity or Luciferase itself, we developed a counter-screen assay for use in 246 confirmation/ validation screens: HEK293 cells stably overexpressing firefly Luciferase 247 controlled by the CMV promoter (Luc assay) ( Figure 1A,B) . 248
We performed the primary screen in ATXN3-Luc cells, employing a 384-well plate format 249 with pools of four individual siRNAs targeting a single gene per well. Pooled siRNAs were tested 250 in triplicate plates for their efficacy to decrease or increase levels of luminescence and to affect 251 cell viability ( Figure 1C ). All plates included built-in controls for luminescence and cell viability 252 readouts (Supplementary Figure 1) : 1) siGENOME RISC-Free Non-Targeting was used as a 253 negative control for both readouts; 2) pooled siGENOME siRNAs targeting ATXN3 were used 254 as a positive control for suppressors of luminescence; 3) because BECN1 was shown to clear 255 ATXN3 in SCA3 mouse models [29, 30] , pooled siGENOME siRNAs against BECN1 were used 256 as positive control for enhancers of luminescence; and 4) cell lysis buffer was used as a positive 257 control for suppressors of cell viability. 258
A total of 33 plates were screened in two assays, showing an average plate Z factor of 259 0.82 for luminescence assessment. Some hits that reduce luminescence may be false positives 260 due to cell death caused by depletion of an essential gene; thus, to identify genes whose 261 knockdown decreases levels of ATXN3 with minimal cell toxicity, we only considered hits that 262 showed cell viability higher than 70% relative to controls. siRNA pools for 317 genes passed this 263 viability cutoff and led to statistically significant increased (N=163) or decreased (N=154) 264 luminescence of at least 50% relative to negative control. 265
These 317 identified candidate genes were similarly distributed throughout the screened 266 protein families: kinases (N=73 of 675, 10.8%), followed by peptidases (N=44 of 412, 10.7%), 267 G-protein coupled receptors (N=43 of 364, 11.8%), proteins with other functions (N=41 of 271, 268 15.1%), ion channels (N=38 of 304, 12.5%), enzymes (N=32 of 311, 10.3%), phosphatases 269 (N=30 of 247, 12.1%), transcription regulators (N=10 of 89, 11.9%), transmembrane receptors 270 (N=3 of 39, 7.7%), transporters (N=2 of 29, 7.7%), and growth factors (N=1 of 2, 50%) 271 (Supplementary Figure 2) . Analysis of subcellular localization of these 317 genes showed that 272 they are mainly distributed through the cytoplasm (N=116), plasma membrane (N=111) and 273 nucleus (N=51) ( Supplementary Figure 2) . 274
Among these 317 hits, we selected 100 genes for confirmation: the top 80 genes whose 275 knockdown decreased luminescence by at least 60%, and the top 20 genes whose knockdown 276 increased luminescence by at least 100% ( Figure 1C ). We chose to select more genes whose 277 knockdown reduced luminescence because our primary goal is to identify therapeutically 278 compelling targets, and it is more feasible to knock down or suppress the activity of a modifier 279 gene as a therapeutic approach. In the confirmation screens, we assessed in parallel the four 280 individual siGENOME siRNAs per gene in ATXN3-Luc and Luc cells ( Figure 1C ). For 33 of the 281 100 genes, we confirmed that at least one siRNA selectively and significantly modulated 282 luminescence levels in ATXN3-Luc cells ( Supplementary Table 2 ): 15 were genes whose 283 knockdown decreased luminescence, and 18 were genes whose knockdown increased 284 luminescence ( Figure 1C) . 285
286
Fifteen genes confirmed to regulate ATXN3 levels in an independent SCA3 cell line 287
We next tested whether knockdown of these 33 genes ( Supplementary Table 2 ) modulated 288 levels of ATXN3 in an independent HEK293 cell model stably overexpressing FLAG-tagged 289 human ATXN3 with a polyQ repeat of 80 (ATXN3Q80 cells) [21] . Cells were transiently 290 transfected individually with each of the four siRNAs targeting an identified gene. The efficiency 291 of transcript depletion was confirmed by quantitative RT-PCR ( Supplementary Figures 3 and 4) , 292
and levels of ATXN3 protein were assessed by Western blot (Figures 2 and 3 ). In this 293 secondary screen, we considered a gene validated as a modifier of ATXN3 abundance if at 294 least two of the four siRNAs altered levels of expanded ATXN3 in the same direction as in the 295 primary screen. 296
Using these criteria, we confirmed 15 of the 33 genes (Table 1) : three enhancers of 297 ATXN3 abundance (i.e. gene knockdown resulted in decreased ATXN3Q80 levels) -MAP3K14, 298 NT5C3A, and FASTK (Figures 2A and B) ; and twelve suppressors of ATXN3 levels (i.e. gene 299 knockdown resulted in increased ATXN3Q80 levels) -CDK8, RNF19A, SIK3, CACNG7, 300 FBXL3, FES, CHD4, HR, MC3R, PKD2, P2RX5, and TACR1 (Figures 3A, B, D and E) . While 301 most of these genes modulated the abundance of both expanded ATXN3Q80 and endogenous 302 wild-type ATXN3, three preferentially regulated expanded ATXN3Q80 levels: MAP3K14, 303 13 RNF19A, and FES (Figures 2 and 3 ). Bioinformatic analysis of these 15 genes revealed a 304 potential molecular network with connections to tumor necrosis factor-a/nuclear factor-kappa B 305 (TNF/NF-kB) and extracellular signal-regulated kinases 1 and 2 (ERK1/2) pathways ( Figure 4) . 306 307 Orthologs of CHD4, FBXL3, HR and MC3R regulate ATXN3Q77-induced toxicity in 308
Drosophila 309
To assess whether the above findings in two cell models are physiologically relevant in vivo, we 310 tested the efficacy of 10 orthologs of identified genes to alter mutant ATXN3-mediated toxicity in 311 a Drosophila model of SCA3 [13, 28, 31] : CACNG7, CHD4, CDK8, FASTK, FBXL3, FES, HR, 312 MC3R, PKD2, and TACR1. For simplicity, we focused on the fly eye expression model which is 313 commonly used to examine the role and pathogenicity of various misfolded proteins [32] . 314
Expression of pathogenic ATXN3 (Q77) in fly eyes is insufficiently toxic to cause marked 315 degeneration of external structures [28, 31] , necessitating the examination of internal eye 316 structures for degenerative phenotypes or the use of a membrane-targeted GFP molecule 317 (CD8-GFP) as a simple readout of the loss of the functional unit of the fly eye, the ommatidium 318
[23]. Through this second assay, a toxic protein such as pathogenic ATXN3 is expressed in fly 319 eyes independently of CD8-GFP; whereas the outside part of the fly eye seems unperturbed by 320 the presence of the toxic protein, internal structures degenerate and photoreceptor cells 321 disappear, resulting in the loss of GFP fluorescence [23] . Thus, increased GFP fluorescence 322 reflects improved eye structure, whereas loss of fluorescence signifies internal eye structure 323 degeneration [23, 25, 26] . In other words, this assay provides a quantifiable degenerative 324 phenotype (reduced GFP) that facilitates screening [25] . In this model, UAS-CD8-GFP and 325 UAS-ATXN3Q77 are driven independently by an eye-restricted driver, GMR-Gal4, through the 326 binary Gal4-UAS system [33] . As shown in Figure 5A , expression of pathogenic ATXN3 in fly 327 eyes leads to a statistically significant loss of GFP signal, as shown before [23] . 328 For each of the 10 genes described above, we crossed RNAi Drosophila lines identified 329 by BLAST analysis and FlyBase reports ( Supplementary Table 3 ) to CD8-GFP & ATXN3Q77 330 flies, and then quantified GFP signal in dissected fly heads at day 7 ( Figures 5B,C) . RNAi 331 targeting seven of 10 genes (orthologs of CHD4, FBXL3, FES, HR, MC3R, PKD2, and TACR1 ) 332 resulted in statistically significant effects on ATXN3-mediated changes in GFP fluorescence in flt 333 eyes ( Figures 5B,C) , consistent with the observed modulation of ATXN3 levels in mammalian 334 cells (Figures 2 and 3) , that is increased toxicity in fly eyes and increased levels of mutant 335 ATXN3 in cells. In contrast, knockdown of orthologs of CACNG7, CDK18 and FASTK in CD8-336
GFP & ATXN3Q77 flies led to results incongruent with cell-based data ( Figure 5B ). To evaluate 337 the baseline effect of knockdown of these 10 genes on eye toxicity, we crossed the RNAi lines 338 with CD8-GFP flies in the absence of ATXN3Q77 and observed the following compared with 339 controls: 1) no differences on GFP signal for crosses with CHD4-1,2,3, FBXL3-1, MC3R-3, 340
PKD2-1, TACR1-1,2 and FASTK-1 lines; 2) decreased GFP intensity in FES-1, HR-1,2, and 341 MC3R-2,4 crosses; and 3) increased fluorescence in CACNG7-1, FASTK-2, CDK18-1,2,3 and 342 PKD2-2 crosses (Supplementary Figure 5) . Overall, the baseline toxicity of the RNAi lines on fly 343 eyes did not interfere with the observed effect on ATXN3-mediated toxicity in crosses of CD8-344 GFP & ATXN3Q77 flies. 345
We next evaluated the effect of these seven genes on ATXN3-mediated disruption of 346 internal eye structures ( Figure 6A ). Histological analyses of eye sections confirmed that 347 knockdown of the orthologs for four genes (CHD4, FBXL3, HR, and MC3R) enhanced 348 ATXN3Q77 toxicity ( Figure 6A) , highlighted by increased separation of retinal structures from 349 the underlying lamina. While no apparent differences in eye structure were observed in crosses 350 of ATXN3Q77 with RNAi lines for orthologs of FES, PKD2 and TACR1, fly heads from all seven 351 crosses showed increased levels of ATXN3Q77 protein ( Figure 6B and Supplementary Figure  352 6), in accordance with our expectations from the cell-based assays described above (Figure 3) . 353
Among the seven orthologs for which we confirmed modulation of ATXN3Q77-mediated toxicity, 354 CHD4, FBXL3, HR, and MC3R surfaced as the top toxicity suppressor genes to pursue further 355 because gene knockdown resulted in concordant outcomes in all three readouts of toxicity or 356 protein abundance in flies (fluorescence intensity, histology and Western blot). 357
358
Overexpression of FBXL3 suppresses ATXN3 abundance in a CUL1-dependent manner in 359
SCA3 neuronal progenitor cells (NPCs) 360
We selected FBXL3 to further confirm its role in regulating mutant ATXN3 abundance in human 361 cells expressing pathogenic ATXN3 from the endogenous locus, namely SCA3 hESC-derived 362
NPCs. FBXL3 was chosen for further analysis because its protein is directly implicated in 363 mechanisms of protein degradation. FBXL3 encodes a F-box protein that is a component of the 364 ubiquitin protein ligase complex SKP1-Cullin1-F-box (SCF) involved in ubiquitin-dependent 365 protein degradation [34] . We first generated NPCs from control and SCA3 hESCs [35] and 366 confirmed that these cells express the markers of neural progenitor lineage PAX6, SOX1 and 367 Nestin ( Figure 7A ). In confirming ATXN3 expression in these cells by immunofluorescence, we 368 observed increased ATXN3-positive puncta in the nucleus and cytoplasm of SCA3 NPCs 369 compared to control NPCs ( Figure 7B) . 370
We overexpressed FBXL3 in SCA3 NPCs and confirmed that high levels of FBXL3 371 reduce endogenous levels of both wild-type and mutant ATXN3 proteins to 58% and 64%, 372 respectively, of control levels ( Figure 7C ). To evaluate if FBXL3-mediated reduction of ATXN3 373 abundance occurs via the SCF/CUL1 ubiquitination complex, we co-electroporated plasmid 374 overexpressing FBXL3 while also decreasing CUL1 with siRNAs against CUL1 ( Figure 7C) . 375
Knockdown of CUL1 abolished FBXL3-mediated reduction of normal ATXN3, but only 376 accounted for about half of the observed FBXL3-facilitated decrease of pathogenic ATXN3 377 ( Figure 7C ), suggesting that FBXL3 handles or recognizes normal and mutant ATXN3 378 differently. Overexpression of FBXL3 and knockdown of CUL1 were confirmed at the transcript 379 level ( Supplementary Figure 7) . ATXN3 transcript levels, although variable across experiments, 380 were actually higher when FBXL3 was overexpressed, with or without knockdown of CUL1 381 ( Supplementary Figure 7) indicating that the observed FBXL3-mediated reduction of ATXN3 382 levels occurs at the protein rather than transcriptional level, as expected. 383
To further explore the role of FBXL3/SCF in modulating ATXN3 protein levels we treated 384 SCA3 NPCs with MLN-4924, an inhibitor of Cullin-RING E3 ubiquitin ligase (CRL) activation, in 385 the presence or absence of FBXL3 overexpression. Baseline MLN-4924 treatment increased 386 levels of wild-type ATXN3 to 277% of control levels and showed a trend, albeit not statistically 387 significant, to increase mutant ATXN3 to 131% of controls ( Figure 7D ). This result implies that 388 SCF and CRL complexes mediate normal ATXN3 clearance, presumably via ubiquitin-389 dependent degradation, to a greater extent than mutant ATXN3 clearance. In addition, the effect 390 of MLN-4924 on normal ATXN3 was largely countered by overexpressing FBXL3 (134% of 391 control levels) ( Figure 7D ). Collectively, while these results implicate SCF and CRL complexes 392 as regulators of ATXN3 protein levels; they also suggest that the action of FBXL3 on ATXN3 393 may be multifaceted. The fact that FBXL3 can counter some of the effects of inhibiting SCF and 394 CRL on wild-type ATXN3, but not pathogenic ATXN3, raises the possibilty of differential 395 regulation of the two forms of ATXN3. 396 397
Discussion 398
There are currently no disease-modifying therapies for SCA3. Reducing levels of mutant ATXN3 399 transcript or encoded protein, however, has effectively mitigated disease phenotypes in 400 preclinical trials in SCA3 transgenic mouse models [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] 36] . Accordingly, therapeutic 401 approaches that deplete pathogenic ATXN3 proteins in the SCA3 brain appear promising. While 402 some evidence suggests that expanded polyQ ATXN3 can be degraded by the proteasome [37-403 42] or macroautophagy [43, 44] and that its stability is affected by specific protein interactions 404 [38, 45, 46] , we lack comprehensive knowledge of the pathways controlling the abundance of 405 mutant ATXN3. Because ATXN3 is a deubiquitinating enzyme that participates in ubiquitin-406 dependent protein quality control pathways [47] [48] [49] [50] , the way cells handle this particular protein 407 could be unusually complex. This knowledge prompted the unbiased druggable genome siRNA 408 screen reported here, which identified several genes as regulators of ATXN3 protein 409 abundance. Because proteins encoded by druggable genes can be inhibited or activated by 410 drugs, the genes discovered here represent compelling therapeutic targets in SCA3 and 411 possibly other polyQ diseases. Our additional studies of one identified gene, FBXL3, also offer 412 new insights into the cellular pathways by which ATXN3 is likely degraded. 413
Employing an iterative screening platform that leveraged a broad range of methods to 414 detect changes in pathogenic ATXN3 levels and toxicity, we successively identified: i) 33 of 415 2742 druggable genes as specific modulators of ATXN3 using a cell-based ATXN3-Luc assay; 416 ii) 15 of 33 genes whose knockdown significantly decreased or increased levels of pathogenic 417 ATXN3 protein in a secondary SCA3 cell model; iii) seven of 10 ortholog genes in Drosophila 418 whose knockdown increased mutant ATXN3-mediated toxicity, assessed by fluorescence signal 419 in eyes of CD8-GFP & ATXN3Q77 flies; and iv) four of seven fly ortholog genes whose 420 knockdown increased mutant ATXN3 abundance and showed disrupted internal eye structures 421 in ATXN3Q77 flies. Of these four genes we then selected one, FBXL3, for further mechanistic 422 studies, which showed that FBXL3 regulates wild-type and pathogenic ATXN3 levels in human 423 SCA3 NPCs, primarily via a SCF complex-dependent pathway. 424
Our primary screen identified 317 genes equally distributed through the categories of 425 enhancers (N=163) and suppressors (N=154) of ATXN3-Luc signal in controls. These genes 426 distributed similarly over different protein function categories, implying that a variety of classes 427 of proteins are involved at some level with handling ATXN3. This is not an unexpected outcome 428 since ATXN3 has been implicated in various cellular processes through its DUB activity [3, 47-429 52] . Among the genes that arose from secondary assays, fifteen are related to TNF/NF-kB and 430 ERK1/2 pathways, indicating that pathogenic ATXN3 levels may be affected by TNF-or 431 mitogen-dependent signaling. TNF, a cytokine mainly produced by glial cells in the brain, either 432 promotes inflammation through the NF-kB pathway and apoptotic cell death, or is 433 neuroprotective, depending on the precise receptors it binds to [53] . The mitogen-activated 434 protein kinases (MAPKs) ERK1/2, also connected with the TNF/NF-kB pathway, likewise can 435 either promote neuronal survival or neuronal death [54] . Glia is understudied in SCA3, but 436 several recent findings suggest key roles for glia and inflammatory signaling in SCA3: early 437 transcriptional changes in SCA3 mouse oligodendrocytes [55] , the contribution of astrocyte-like 438 glia to non-cell autonomous degeneration in SCA3 flies [56] , and neuroprotection from the 439 NSAID ibuprofen in a SCA3 mouse model [57] . Our findings that pathogenic ATXN3 protein 440 levels can be regulated by TNF/NF-kB and ERK1/2 pro-inflammatory and cell death/survival 441 pathways highlight the need for further investigation of their role in SCA3. 442
Genes and proteins that regulate pathogenic ATXN3 abundance and toxicity yet have a 443 limited number of substrates and/or effectors would be ideal targets for intervention in SCA3. 444
Among such candidates, the F-box protein FBXL3, which binds substrates and promotes their 445 ubiquitination and subsequent degradation [34], peeked our interest. Our observation that 446 FBXL3 regulates levels of endogenous wild-type and pathogenic ATXN3 in human SCA3 NPCs, 447 supports the view that ATXN3 is a substrate for FBXL3 under physiological conditions reflective 448 of the human disease. While only a few FBXL3 substrates have been validated, 141 proteins 449 were recently identified as being potentially recruited to SCF FBXL3 complexes by cryptochromes 450 CRY1 and CRY2, which are themselves FBXL3 substrates [58] [59] [60] . It remains, however, to be 451 determined whether targeting FBXL3 will prove to be a viable therapeutic strategy in SCA3. On 452 the one hand, null FBXL3 mutations cause autosomal recessive developmental delay and 453 intellectual disability [61] suggesting that FBXL3 mediates the stability of numerous proteins and 454 that complete loss of FBXL3 function is harmful for cells, at least during development. On the 455 other hand, FBXL3 knockdown in our mammalian cell lines and in flies did not show 456 accompanying toxicity ( Supplementary Table 2 and Supplementary Figure 5 ). Further studies 457 will be needed to establish whether increasing or decreasing FBXL3 has effects on the fully 458 developed adult brain, which is the relevant target in age-related neurodegenerative diseases 459 such as SCA3. 460
If FBXL3 knockdown increases ATXN3 abundance, then its overexpression would be 461 expected to decrease ATXN3 protein levels. Exogenous expression of FBXL3 in SCA3 NPCs 462 indeed reduced the levels of both wild-type and pathogenic ATXN3. The potential role of the 463 SCF and potentially other CRL complexes in ubiquitinating and regulating ATXN3 levels 464 appears to span to both wild-type and pathogenic forms of this DUB. Supporting evidence for 465 the particular involvement of the SCF complex in ATXN3 ubiquitination comes from a recent 466 report showing that CUL1 and FBXO33 specifically interact and promote ubiquitination and 467 solubility of a truncated form of pathogenic ATXN3 [62], and from an independent yeast-two-468
hybrid study that identified the mouse homologs Cul1 and Atxn3 as interacting partners (Costa 469 et al. unpublished observations) . As ATXN3 shows both DUB and deneddylase activities in vitro 470
[63], future work should investigate its functions in pathways regulated by SCF and CRL 471 complexes and the effect that these complexes have on ATXN3. 472 473
Conclusions 474
We identified 15 druggable genes that implicate the involvement of TNF-or mitogen-475 dependent signaling cascades in regulating pathogenic ATXN3 levels. One of these potential 476 candidates for SCA3 intervention, FBXL3, is directly involved in protein quality control and was 477 effective in modulating the levels of mutant and wild-type ATXN3 under physiological conditions 478 in human cells. The proteins encoded by these genes and the pathways in which they are 479 implicated demand further evaluation to understand the pathobiology of SCA3 and to seek 480 disease-modifying therapies for this fatal disorder. 
